MiR‐134‐5p attenuates neuropathic pain progression through targeting Twist1

Neuropathic pain is a kind of chronic pain because of dysfunctions of somatosensory nerve system. Recently, many studies have demonstrated that microRNAs (miRs) play crucial roles in neuropathic pain development. This study was designed to investigate the effects of miR‐134‐5p on the process of neuropathic pain progression in a rat model established by chronic sciatic nerve injury (CCI). First, we observed that miR‐134‐5p was significantly decreased in CCI rat models. Overexpression of miR‐134‐5p strongly alleviated neuropathic pain behaviors including mechanical and thermal hyperalgesia. Meanwhile, inflammatory cytokine expression, such as IL‐6, IL‐1β and TNF‐α in CCI rats were greatly repressed by upregulation of miR‐134‐5p. Twist1 has been widely regarded as a poor prognosis biomarker in diverse diseases. Here, by using bioinformatic analysis, 3′‐untranslated region (UTR) of Twist1 was predicted to be a downstream target of miR‐134‐5p in our study. Here, we found that overexpression of miR‐134‐5p was able to suppress Twist1 dramatically. Furthermore, it was exhibited that Twist1 was increased in CCI rats time‐dependently and Twist1 was inhibited in vivo. Subsequently, downregulation of Twist1 in CCI rats could depress neuropathic pain progression via inhibiting neuroinflammation. In conclusion, our current study indicated that miR‐134‐5p may inhibit neuropathic pain development through targeting Twist1. Our findings suggested that miR‐134‐5p might provide a novel therapeutic target for neuropathic pain. Our study demonstrated a role of miR‐134‐5p/Twist1 axis in neuropathic pain progression. It was exhibited that miR‐134‐5p alleviated neuropathic pain of CCI rats by targeting Twist1. Our findings indicated that miR‐134‐5p could be identified as a novel biomarker for neuropathic pain.